Hudson Bay Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$37.4M Buy
292,500
+92,500
+46% +$11.5M 0.13% 136
2025
Q4
$24.4M Buy
+200,000
New +$22.9M 0.08% 203
2025
Q2
Sell
-575,000
Closed -$46.6M 1680
2025
Q1
$46.6M Buy
575,000
+425,000
+283% +$38M 0.14% 139
2024
Q4
$13.5M Buy
+150,000
New +$14.5M 0.05% 307
2023
Q4
Sell
-100,000
Closed -$7.3M 912
2023
Q3
$7.3M Buy
+100,000
New +$7.99M 0.06% 213

Other funds holding XBI

Hudson Bay Capital Management's XBI Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 255 shares worth $32.6K. The stake represents ﹤0.01% of the portfolio and ranks #1299 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in XBI as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in XBI in Q2 2020 and has held it in 7 quarters since. The position peaked at $11M in Q1 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Hudson Bay Capital Management held 255 shares of State Street SPDR S&P Biotech ETF worth $32.6K as of Q1 2026.
  • State Street SPDR S&P Biotech ETF was a new Hudson Bay Capital Management position in Q1 2026.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1299 holding.
  • Hudson Bay Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and has held it in 7 quarters since.
  • Hudson Bay Capital Management's State Street SPDR S&P Biotech ETF position peaked at $11M in Q1 2025.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.